Sunday, September 13, 2026

U.S.-Korea Nuclear Submarine Deal: What to Expect from February Delegation?

The U.S. will send a delegation to South Korea to discuss nuclear cooperation, submarines, and shipbuilding agreements by February.

President Lee Questions Rodong Sinmun Ban, Asking If Government Treats Citizens As Vulnerable To Red Propaganda

President Lee Jae Myung advocates for public access to North Korea's Rodong Sinmun, questioning the rationale behind restrictions.

North Korea Expands Cyberattacks, Suspected of Breaching South Korea’s Government Document System

North Korea is suspected of hacking South Korea's document system, leading to data breaches and concerns over cybersecurity vulnerabilities.

Tag: Celltrion

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Celtrion’s Steqeyma Seizes 16% Market Share in the U.S.: What’s Next for This Autoimmune Treatment?

Celltrion's autoimmune drug Steqeyma surpasses 16% market share in the U.S., accelerating prescription growth and expansion.

“Second-Half Performance to Outpace First Half”… Celltrion Expected to Exceed Full-Year Revenue Target

Celltrion is expected to outperform its first-half results in the second half, driven by new-product growth, European tender wins and stronger demand for high-margin products, potentially allowing it to exceed its full-year targets.

Unlocking the Future: Why 340,000 Families Trust Celltrion’s Cord Blood Banking in 2026

Medipost announces that its brand, Celltrion, has surpassed 340,000 cord blood storage units in South Korea.

Celltrion’s CT-P51: Will This Keytruda Biosimilar Disrupt the 44 Billion USD Cancer Drug Market?

Celltrion has applied for approval of its biosimilar CT-P51 for the global blockbuster immuno-oncology drug Keytruda (pembrolizumab).

Celltrion Completes Integration of France’s Gifrer, Targets European Pharmacy Network

Celltrion has completed the post-acquisition integration of French health care company Gifrer and plans to use its pharmacy network as a hub for expanding direct sales across Europe.

Celltrion Publishes Population Pharmacokinetic Analysis of Vegzelma in International Journal

Celltrion has published integrated population pharmacokinetic analysis results for its Avastin biosimilar Vegzelma, confirming pharmacokinetic similarity with the reference drug.

Celltrion’s Three ADC Drug Candidates All Receive FDA Fast Track Designation

Celltrion has secured U.S. FDA Fast Track designation for all three of its antibody-drug conjugate candidates, accelerating development of its emerging oncology drug pipeline.

Celltrion Expands Market Presence With Major Tender Wins in Spain and Portugal

Celltrion is accelerating its expansion in Spain and Portugal through major tender wins, rising prescriptions and a strengthened direct-sales strategy across its biosimilar portfolio.

Celltrion accelerates mechanism diversification strategy, expands autoimmune disease portfolio

Celltrion accelerates the development of biosimilars for autoimmune disease treatments, expanding its portfolio for long-term growth.

Celltrion expands U.S. PBM coverage, boosting outlook for high-margin biosimilars

Celltrion expands its listing with US PBM, enhancing its high-profit biosimilar product base and boosting sales expectations for H2.

Celltrion’s Omlyclo Gains Traction in Italy, Reinforcing Direct Sales Strategy as Growth Expected to Accelerate

Celltrion expands its biosimilar supply in Italy, enhancing its competitiveness in the European pharmaceutical market.

Celltrion Files for European Approval of Cosentyx Biosimilar, Targets $6.7 Billion Market

Celltrion has filed for European approval of its CT-P55 biosimilar for autoimmune diseases, aiming for early market entry and expansion.

Celltrion Group’s 2 Trillion KRW Investment: What It Means for Global Bio Manufacturing by 2032

Celltrion Group plans a 2 trillion KRW investment to enhance production capacity and establish a leading position in global biotech.

Celltrion Expands PFS Production Capacity to 70 Million: What This Means for the Global Market

Celltrion Pharmaceutical plans to invest 2 trillion KRW to expand its pre-filled syringe production capacity to meet global demand.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.